NERV MEXC RealStocks
Own real NERV shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-18 17:12:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Minerva Neurosciences, Inc. (NERV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.19, with a market capitalization of $109.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.96 to $8.80. This page covers its latest market performance, valuation, price trends and company information.
$109.64M | |
$2.15 | |
$2.35 | |
$2.10 | |
$2.16 | |
186.82K | |
161.97K | |
-- | |
$8.80 | |
$1.96 | |
-- | |
2026-09-30 |
Minerva Neurosciences, Inc. (NERV) is currently trading at $2.19 as of 2026-11-18 17:11:00, down 2.31% ($0.05) from the previous close of $2.16
During today's regular trading session, NERV has traded between $2.10 and $2.35, with a trading volume of 186.82K shares. The current price is near the middle of today's range.
Over the past seven days, Minerva Neurosciences, Inc. (NERV) moved from $2.63 to $2.19, representing a decline of 16.88% ($0.44).
The stock traded between $2.04 and $2.76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 143.19 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.3%
NERV is currently trading at $2.19, placing it 3.3% of the way from its 52-week low of $1.96 to its 52-week high of $8.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Minerva Neurosciences, Inc. (NERV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NERV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between NERV shares and USD.
NERV Shares to USD
1.00 NERV shares = 2.186 USD
Calculations are estimates based on the latest available price and are for reference only.